Focus Partners Wealth
ASBP

Focus Partners Wealth’s Aspire Biopharma ASBP Stock Holding History

Focus Partners Wealth’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$2.58K – 2798
2025
Q3 		$2.58K Buy
+10
New +$5.01K ﹤0.01% 2198

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
RA
Resolute Advisors San Francisco, California $242M AUM 52.95% 1-Year Est. Return

Focus Partners Wealth's ASBP Position: Q4 2025 in Review

Focus Partners Wealth sold out of Aspire Biopharma (ASBP) in Q4 2025, closing a stake of 10 shares — an estimated $2.58K sold.

Focus Partners Wealth first reported a position in ASBP in Q3 2025 and held it in 1 quarter. The position peaked at $2.58K in Q3 2025. 28 funds tracked by Wall St. Rank hold ASBP as of Q4 2025.

  • Focus Partners Wealth reported no remaining Aspire Biopharma position as of Q4 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 10 Aspire Biopharma shares in Q4 2025, an estimated $2.58K.
  • Focus Partners Wealth first reported a position in Aspire Biopharma in Q3 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Aspire Biopharma position peaked at $2.58K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2025.

Based on Focus Partners Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.